Institutional Repository UDD

What's New in the Treatment of Enterococcal Endocarditis?

Show simple item record Nigo, Masayuki Munita, Jose Arias, Cesar Murray, Barbara 2017-04-05T15:03:37Z 2017-04-05T15:03:37Z 2014
dc.identifier.citation Curr Infect Dis Rep. 2014 Oct;16(10):431 es_CL
dc.identifier.uri es_CL
dc.description.abstract Enterococcus spp. are among the common pathogens causing infective endocarditis (IE). Despite major medical advances and new potent antimicrobial agents, the mortality has not significantly improved for several decades. The usual lack of bactericidal activity of penicillin or ampicillin, the toxicity from the combination of penicillin plus aminoglycosides, and the increased reports of high-level resistance to aminoglycosides have led to the exploration of other regimens for treatment of Enterococcus faecalis IE. As an example, ampicillin plus ceftriaxone is now a well-recognized regimen for this organism. However, the emerging of new drug resistances in Enterococcus faecium dramatically reduces the therapeutic alternatives for this organism in IE which continues to be an immense challenge for clinicians even with the availability of newer antimicrobial agents. This article summarizes the current treatment options for enterococcal endocarditis and reviews of recent publications on the topic. es_CL
dc.format.extent 17 es_CL
dc.language.iso en_US es_CL
dc.publisher Springer es_CL
dc.subject Endocarditis es_CL
dc.subject Enterococcal es_CL
dc.subject Enterococci es_CL
dc.subject VRE es_CL
dc.subject Enterococcus es_CL
dc.title What's New in the Treatment of Enterococcal Endocarditis? es_CL
dc.type Artículo es_CL

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account